... is a risk of developing HIV resistance if SUSTIVA is underdosed. Bristol-Myers Squibb remains at the forefront of HIV/AIDS research and continues to pursue the development of treatment options for children and adults with HIV. Studies are ongoing ...
http://www.drugs.com/newdrugs/bristol-myers-squibb-receives-us-fda-snda-approval-sustiva-efavirenz-hiv-1-infected-pediatric-3775.html
http://www.drugs.com/newdrugs/bristol-myers-squibb-receives-us-fda-snda-approval-sustiva-efavirenz-hiv-1-infected-pediatric-3775.html
No comments:
Post a Comment